linjc16/ctgov huggingface dataset:
The Management of Sportsman's Groin Hernia in Professional and Amateur Soccer Players

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the surgical treatment for sportsman's hernia in our department to the current literature. Our hypothesis is that combined solution for the two major problems that cause pain in this syndrome - repair the weakness in the posterior wall of the inguinal canal with tension free technique (mesh repair) and reducing the muscle strain on the abdominal wall by cutting, partially, the tendon of the external oblique muscle, will shorten the time to return to full physical activity in soccer players.

Official Title
-----------------
A Study, Based on Medical Record and Questionnaire, Investigate the Management of Sportsman's Groin Hernia in Professional and Amateur Soccer Players -Results of the Follow-up in Our Department and a Comparison the Medical Literature

Conditions
-----------------
Sportsman's Groin Hernia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Soccer players who reffered to our clinic soccer players diagnosed with sportsman's hernia Failure of conservative treatment Underwent conventional surgery for sportsman's hernia in our department Completed the follow-up in our clinic age : 14-40 male and female Exclusion Criteria: soccer players who were diagnosed of had there surgery in other places soccer players who recover after conservative treatment

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to return to full physical activity |  | 2 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain after the surgery |  | 1 week, 2 weeks and 4-6 month |
Endoscopic Closure of Tracheoesophageal Fistulas With Occluder Device

Study Overview
=================
Brief Summary
-----------------
Endoscopic closure of tracheoesophageal fistulas with a device used for closure of cardiac septal defects.

Official Title
-----------------
Endoscopic Closure of Tracheoesophageal Fistulas With a Cardiac Septal Defect Occluder

Conditions
-----------------
Acquired Tracheo-esophageal Fistula

Intervention / Treatment
-----------------
* Device: Fistula closure with Gore Helex Septal Occluder
* Device: Gore Helex Septal Occluder


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 14 years old Benign tracheoesophageal fistulas identified through bronchoscopy; Exclusion Criteria: Malign neoplasia Current mechanical ventilation Immunosuppressed Current local inflammatory process at fistulas borders Other clinical risk factors

Ages Eligible for Study
-----------------
Minimum Age: 14 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Fistula closure with occluder<br>Patients with benign tracheoesophageal fistulas will be submitted to the correction with the occluder. | Device: Fistula closure with Gore Helex Septal Occluder<br>* The occluder will be released at the tracheoesophageal fistoulous traject through endoscopic procedures<br>Device: Gore Helex Septal Occluder<br>* Fistula closure with endoscopic release of occluder in the fistula traject.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Closure of tracheoesophageal fistulas with the Gore Helex Septal Occluder | The closure will be confirmed by endoscopic or bronchoscopic observation of the fistula at regular intervals: one week, two weeks, and four weeks after implant of the occluder. A thorax CT scan will ascertain correct positioning and stability of the occluder. | 6 months |
Relationship Between Footwear Consumer Behaviour and Lower Extremity Injuries

Study Overview
=================
Brief Summary
-----------------
A prospective cohort study was set-up in leisure-time walkers and runners. Potential risk factors in consumer behaviour were obtained by means of a baseline questionnaire related to the acquisition of current walking or running shoes. Information on injuries sustained during a 24 week period after the baseline questionnaire was obtained in 104 runners and 104 walkers using a 2-weekly questionnaire.

Official Title
-----------------
Is Consumer Behaviour Towards Footwear Predisposing for Lower Extremity Injuries in Runners and Walkers? A Prospective Study

Conditions
-----------------
Risk Factor, Sports Injury, Footwear

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: walk or run at least 10 kilometres per week maintain a minimal distance of ten kilometres per week, for a period of 24 weeks wear one and the same pair of shoes during walking/running activities during this period Exclusion Criteria: systemic disease, cardiac problems or diabetes complaints at the lower extremities in the last two weeks, surgery at the lower extremities in the last three years
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| injury occurence | self-reported running or walking injury questionnaire | 24 weeks |
Diabetes Mellitus With Pregnancy in Benisuef Localities

Study Overview
=================
Brief Summary
-----------------
The aim of this work is to demonstrate the variation of Diabetes mellitus either preexisting or gestational Diabetes mellitus among pregnant ladies in our localities, detect maternal & fetal complications and to predict the risk factors for poor maternal, fetal & neonatal outcomes

Official Title
-----------------
Diabetes Mellitus With Pregnancy in Benisuef Localities

Conditions
-----------------
Pregnancy in Diabetics

Intervention / Treatment
-----------------
* Other: observation registry


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all pregnant ladies with Diabetes mellitus either type 1 or type 2 all pregnant ladies with glucose intolerance which is first diagnosed during current pregnancy Exclusion Criteria: ladies age less than 18 year or above 45

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| preexisting Diabetes mellitus type 1<br> | Other: observation registry<br>* observation registry<br>|
| preexisting Diabetes mellitus type 2<br> | Other: observation registry<br>* observation registry<br>|
| Gestational Diabetes mellitus<br> | Other: observation registry<br>* observation registry<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maternal outcome | No. of patients who have preeclampsia,eclampsia,preterm delivery,Cesarean section,vaginal candidiasis,premature rupture of membrane,polyhydramnios,oligohydramnios,accidental hemorrhage,birth canal injuries,puerperal sepsis,wound infection,postpartum glucose intolerance. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| fetal outcome | No. of abortion,prematurity,macrosomia,congenital anomalies,intrauterine fetal death,still birth,shoulder dystocia,brachial plexus injury,neonatal death,respiratory distress syndrome,neonatal jaundice requiring photo-therapy,neonatal hypoglycemia, | 2 years |
The Effect of Cerclage Pacing for the Heart Failure Patients Who Need Cardiac Resynchronization Therapy (CRT)

Study Overview
=================
Brief Summary
-----------------
trans-coronary sinus intraseptal pacing (cerclage pacing)

Detailed Description
-----------------
This study is aimed at looking at the effect of Cerclage pacing for the heart failure patients who need cardiac resynchronization therapy (CRT). The study hypothesis is that parahisian pacing by 'cerclage pacing' may have a similar benefit as is seen with permanent Hisian pacing

Official Title
-----------------
The Effect of Cerclage Pacing for the Heart Failure Patients Who Need Cardiac Resynchronization Therapy (CRT): Early Feasibility Study

Conditions
-----------------
Heart Failure, LBBB Complete

Intervention / Treatment
-----------------
* Device: Medtronic 4196 lead


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: who need cardiac resynchronization therapy (CRT) or CRT-non responder Left bundle branch block [LBBB]) > 120ms of QRS width Ejection fraction (EF) < 35% NYHA class III-IV in spite of optimal medical Tx Exclusion Criteria: Unsuitable coronary vein anatomy on cardiac CT Subjects with prosthetic mechanical tricuspid valve Active infection Life expectancy less than 6 months

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: patients who meet the criteria of current CRT treatment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cerclage-CRT (medtronic 4196 lead)<br>trans-coronary sinus intraseptal pacing (cerclage pacing) which technology to position the pacemaker lead into the septum for 'parahisian pacing' | Device: Medtronic 4196 lead<br>* Cerclage-CRT pacing with Medtronic 4196 lead (Attain Ability Lead)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of procedural success | Narrowing QRS by 20% or greater compared with baseline QRS width | immediate postprocedure | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in subjects' symptoms referred to NYHA Classification System | NYHA (New York Heart Association) : +1 grade | 12 months | 
| Change in subjects' improvement of parameters by Echocardiography | Ejection Fraction +5% | 12 months | 
| Change of Six minute walk Distance | improvement of SMWD | 12 months | 
| interrogation index of pacemaker lead | interrogation index of pacemaker lead | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cerclage pacing, cerclage-CRT, wide QRS
Cerebral Blood Flow Velocity Changes During Laparoscopic Surgery

Study Overview
=================
Brief Summary
-----------------
Little is known about how implementation of pneumoperitoneum contributes to cerebral blood flow in pediatrics. We investigated this question in patients undergoing laparoscopic surgery, hypothesizing that cardiorespiratory changes during this procedure would reduce cerebral perfusion.

Official Title
-----------------
A Study on Cerebral Blood Flow Velocity Changes During Laparoscopic Surgery in Pediatric Patients: Observational Study Using Transfontanelle Ultrasound

Conditions
-----------------
Cerebral Blood Flow

Intervention / Treatment
-----------------
* Diagnostic Test: Transfontanelle ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pediatric patients undergoing laparoscopic surgery Exclusion Criteria: -

Ages Eligible for Study
-----------------
Maximum Age: 2 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Transfontanelle ultrasound|cerebral blood flow measurement using transfontanelle ultrasound|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cerebral blood flow | cerebral blood flow measurement using transfontanelle ultrasound | intraoperative |
Role of Metabolomics in the Diagnosis of Endometriosis

Study Overview
=================
Brief Summary
-----------------
Endometriosis is one of the most common benign gynecological, affecting about 10% of premenopausal women. The pathophysiology of this disease is still not completely clear. Despite its prevalence, there is no blood test available for the diagnosis of endometriosis and the average delay time to diagnosis is 9.4 years. Metabolomics is a scientific discipline that studies changes in metabolites related to the pathophysiology of the disease. Aim of the study is to identify an alteration in the expression of the metabolites in women with endometriosis

Official Title
-----------------
Role of Metabolomics in the Diagnosis of Endometriosis

Conditions
-----------------
Endometriosis

Intervention / Treatment
-----------------
* Procedure: laparoscopic surgery, obtainment of biological samples


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: women of childbearing age ; written consent to laparoscopic surgery; written consent to the study . Exclusion Criteria: Suspicion or diagnosis of malignant disease Inability or unwillingness to provide written consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Endometriosis<br>Patients will undergo laparoscopic surgery in order to treat endometriosis. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood, with the purpose to study metabolitis, will be collected before surgery. | Procedure: laparoscopic surgery, obtainment of biological samples<br> <br> |
| Controls<br>Patients will undergo laparoscopic surgery in order to treat benign gynecological diseases. Biopsies will be performed for histological confirmation of the disease. Samples of urine and blood,with the purpose to study metabolitis, will be collected before surgery. | Procedure: laparoscopic surgery, obtainment of biological samples<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma and urine concentration of metabolites |  | At least one month after discontinuation of hormonal therapies , before laparoscopic surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endometriosis, Metabolomics
Non Alcoholic Fatty Liver Disease (NAFLD) in Hong Kong

Study Overview
=================
Brief Summary
-----------------
The true incidence and prevalence of NAFLD in Hong Kong has not been determined. The natural history of NAFLD is not well defined partly because of differences in the exclusion limit of alcohol and the required histological criteria between studies. NAFLD is previously believed to be a benign non-progressive condition, but it has since been determined that a subset of patients can progress to cirrhosis and even hepatocellular carcinoma. In fact in a recent histological review of NAFLD, fibrosis or liver cirrhosis was present in 15-50% of patients at index liver biopsy. The presence of obesity or type 2 diabetes mellitus are the strongest predictors of fibrosis. These same risk factors are also more common in patients with cryptogenic cirrhosis. Further evidence of the link between diabetes, obesity and NAFLD are mainly from the field of liver transplantation. In patients who underwent liver transplantation for cryptogenic liver cirrhosis, NAFLD recuured in a quarter of the hepatic allografts. The patients with recurrent NAFLD were more likely to be diabetic and had a higher body mass index (BMI) at the time of recurrent NAFLD. This suggests that NAFLD may have a significant role in the pathogenesis of crytogenic cirrhosis. Although NAFLD was initially described as a slowly progressive disease, there are emerging data which shows that it can progress rapidly. Liver failure has even been described in patients with NAFLD after bariatric surgery, and a recent report described 5 cases of subacute liver failure in obese middle aged females with NAFLD related cirrhosis. NAFLD can also affect the progression of other diseases as well. Hepatic steatosis related to visceral obesity is a major independent risk factor for fibrogenesis related to chronic HCV hepatitis. However, the prevalence of NAFLD and its interaction with chronic HBV, if any, is uncertain. This study aims to determine the prevalence of NAFLD in patients with unknown cause of hepatitis and to determine the histological fibrosis and inflammation in chronic HBV patients with NAFLD.

Official Title
-----------------
Non Alcoholic Fatty Liver Disease (NAFLD) in Hong Kong: Natural History and Development of Liver Complications

Conditions
-----------------
Fatty Liver

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-80 years old Gender: male and female Exclusion Criteria: HBV patients and fatty liver HCV HIV

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NAFLD
The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Study Overview
=================
Brief Summary
-----------------
To compare The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy.

Official Title
-----------------
The Impact on Recurrence Risk of Adjuvant Lenvatinib for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.

Conditions
-----------------
Hepatocellular Carcinoma

Intervention / Treatment
-----------------
* Drug: Lenvatinib


Participation Criteria
=================
Eligibility Criteria
-----------------
No Criteria: Inclusion Criteria: older than 18 years old and younger than 75 years; ECOG PS<3; proven hepatocellular carcinoma with MVI according pathological examination; not previous treated for tumor; tumor was removed in operation; no recurrence occurence at 4 to 7 weeks after surgery; the lab test could meet: neutrophil count≥1.5×109/L; hemoglobin≥80g/L; platelet count≥60×109/L; serum albumin≥28g/L; total bilirubin<3-times upper limit of normal; ALT<5-times upper limit of normal; AST<5-times upper limit of normal; serum creatine<1.5-times upper limit of normal; PT≤upper limit of normal plus 6 seconds; INR≤2.3; sign up consent; unrolled by other clinical trials about hepatocellular carcinoma. Exclusion Criteria: cannot tolerate lenvatinib; CNS or bone metastasis exits; known history of other malignancy; be allergic to related drugs; underwent organ transplantation before; be treated before (interferon included); known history of HIV infection; known history of drug or alcohol abuse; have GI hemorreage or cardiac/brain vascular events within 30 days; pregnancy;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: treatment group<br>adjuvant lenvatinib | Drug: Lenvatinib<br>* oral lenvatinib after hepatectomy<br>|
| No Intervention: control group<br>no intervention | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| RFS | recurrence-free survival | From date of randomization until the date of recurrence, assessed up to 60 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| OS | overall survival | From date of randomization until the date of death from any cause, assessed up to 60 months | 
| recurrence rate | recurrence rate | 1 year, 2 year, 3 year, 5 year after surgery |
Pituitary Tumor Surveillance: Pathogenic Correlation

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity in patients harboring pituitary mass lesions of all types.

Detailed Description
-----------------
The purpose of this study is to observe predictors of pituitary tumor recurrence and markers of persistent disease activity through computerized collection of comprehensive demographic, therapeutic, pathologic and outcome information on patients harboring pituitary mass lesions of all types.

Official Title
-----------------
Pituitary Tumor Surveillance: Pathogenetic Correlation

Conditions
-----------------
Pituitary Tumor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with confirmed pituitary disease Exclusion Criteria: patients who do not have confirmed pituitary disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pituitary tumor, recurrence